National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231107738739/en/

Bill Marth, President of Services, Resilience (Photo: Business Wire)

In this role, Mr. Marth will have end-to-end responsibility for all development and manufacturing services and commercial activities at Resilience. Resilience’s objective in creating the new Services organization is to strengthen the company’s focus on providing the highest quality execution for pre-clinical, clinical and commercial programs.

“Having worked in the global biopharmaceutical industry for more than thirty years, I know the crucial role that biomanufacturing plays to ensure efficient delivery of important medicines to patients,” said Mr. Marth. “I am thrilled to join the esteemed executive team at Resilience, and I look forward to partnering with the team to deliver on Resilience’s mission.”

Prior to joining Resilience, Mr. Marth previously served as a Director (2012) and Chairman of the Board (2013) of AMRI (NASDAQ) (now known as Curia Global, Inc.) before assuming the role of Chief Executive Officer from 2014 through 2018. In 2017, Mr. Marth led the sale of AMRI to Carlyle and GTCR for $1.65 billion. Additionally, he previously served as President and CEO of Teva Pharmaceuticals Industries Ltd. for the Americas and CEO of Teva North America and Teva USA.

“Bill has an unparalleled record of corporate success, and we are thrilled to welcome a seasoned life sciences industry leader to our team,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “We look forward to benefitting from his experience and capability to better serve our customers and further scale Resilience.”

About Resilience

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231107738739/en/